Mengxi Zhao

发表

Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED

P. Atadja, E. Li, D. Bussiere, 2017, PloS one.

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.

M. P. Dillon, P. Atadja, Youzhen Wang, 2017, Journal of medicinal chemistry.

Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.

P. Atadja, E. Li, Zongyao Wang, 2017, Oncotarget.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

P. Atadja, E. Li, Youzhen Wang, 2017, Nature chemical biology.

Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells

P. Atadja, E. Li, Zongyao Wang, 2017, Oncotarget.

An allosteric PRC 2 inhibitor targeting the H 3 K 27 me 3 binding pocket of EED

P. Atadja, E. Li, Youzhen Wang, 2016 .

Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.

Stephen M. Canham, John A. Tallarico, P. Atadja, 2023, ACS chemical biology.

Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.

Stephen M. Canham, John A. Tallarico, Ying Lin, 2023, Journal of Medicinal Chemistry.